BIOCEPT INC: restructuring charge — Biocept explores strategic alternatives, reduces workforce by 36%, projects $13M cash

BIOCEPT INC

Commenced evaluation of strategic alternatives including acquisition, merger, asset sale; engaged EF Hutton as advisor.
Workforce reduction of approximately 36% expected in Q1 2023; severance and related costs estimated at $0.6M.
Projects year-end 2022 cash balance of about $13M; plans to cease COVID-19 testing at end of January 2023.
CNSide assay remains a focus but company seeks to extend cash runway amid exploration.
No assurance of successful strategic outcome; no further updates unless board approves a specific course.

item 2.02 item 2.05 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

BIOCEPT INC announced a restructuring with charges of approximately $0.6 million (approximately 36%).

Type: restructuring
Charge: approximately $0.6 million
Headcount: approximately 36%

Exact text from the filing

the Company is implementing a restructuring plan that will result in a reduction in the Company’s workforce by approximately 36%. The reduction in force is expected to be completed during the first quarter of 2023. The Company estimates that it will incur charges of approximately $0.6 million for severance and other employee termination-related costs in the first quarter of 2023.

View on SEC.gov

Browse all restructurings & charges →

Source: SEC EDGAR

accession 0001193125-23-002951

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.